Evelyn Partners Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Evelyn Partners Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21K	Hold	47	–	–	0.01%	222
2025 Q4	$21.3K	Hold	47	–	–	0.01%	194
2025 Q3	$18.4K	Buy	47 +38	+422%	+$15.9K	﹤0.01%	200
2025 Q2	$4.01K	Hold	9	–	–	﹤0.01%	218
2025 Q1	$4.36K	Hold	9	–	–	﹤0.01%	225
2024 Q4	$3.62K	Buy	+9	New	+$4.17K	﹤0.01%	229

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Evelyn Partners Asset Management's VRTX Position: Q1 2026 in Review

Evelyn Partners Asset Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 47 shares worth $21K. The position accounts for 0.01% of the portfolio, ranked #222.

Evelyn Partners Asset Management first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $21.3K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Evelyn Partners Asset Management held 47 shares of Vertex Pharmaceuticals worth $21K as of Q1 2026.
Evelyn Partners Asset Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.01% of Evelyn Partners Asset Management's portfolio in Q1 2026, its #222 holding.
Evelyn Partners Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Evelyn Partners Asset Management's Vertex Pharmaceuticals position peaked at $21.3K in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Evelyn Partners Asset Management's 13F filing for Q1 2026, filed 15 May 2026.